Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...
The company is planning to offer Galaxy Store developers an 80 / 20 revenue share on games beginning May 15th. Currently, it’s 70 / 30. According to Seline Sangsook Han, Samsung EVP of Mobile Service ...
Samsung SDI, South Korea’s second-largest battery manufacturer, has announced plans to raise 2 trillion won ($1.37 billion) ...
Samsung currently operates two plants in Mexico, one in Tijuana and one in the city of Querétaro, where the company was ...
This news marks the end of a long wait for many Samsung users, particularly those with devices from the Galaxy S23 and S24 ...
Samsung Bioepis has allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous settlement.
Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the drugmaker over the launch of a biosimilar to Stelara, J&J's autoimmune ...
Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's blockbuster drug Stelara, also known as ustekinumab. The drug is used to ...
(Reuters) - Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to Stelara, J&J's blockbuster psoriasis treatment. The lawsuit ...